Shenyang Pharma Univ. CDK9 compound B11

Shenyang Pharma Univ. CDK9 compound B11: sourced facts only. name: "Among them, compound B11 exhibited comparable in vitro antiproliferative activity to AZD5438 against three colorectal cancer cell lines (HCT116, RKO, and HT-29), along with superior selectivity for CDK9 inhibition, displaying an IC50 of 7.13 nM." [PMID:41086724]; target: "Among them, compound B11 exhibited comparable in vitro antiproliferative activity to AZD5438 against three colorectal cancer cell lines (HCT116, RKO, and HT-29), along with superior selectivity for CDK9 inhibition, displaying an IC50 of 7.13 nM." [PMID:41086724]; developer: "Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China." [PMID:41086724]; modality: "This study designed and synthesized two series (A and B) of 28 unreported compounds based on rational structural modification of the lead compound AZD5438." [PMID:41086724]; stage: "Mechanistic studies demonstrated that B11 induces apoptosis in HCT116 cells by elevating intracellular ROS levels through suppression of anti-apoptotic protein expression and activating the caspase-3 pathway." [PMID:41086724]